CABALETTA BIO, INC. Gain (Loss) on Termination of Lease
CABALETTA BIO, INC. (CABA) reported Gain (Loss) on Termination of Lease of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2024-03-21
- CABALETTA BIO, INC. gain (loss) on termination of lease for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CABALETTA BIO, INC. gain (loss) on termination of lease for fiscal 2022 was $149.00K.
- CABALETTA BIO, INC. gain (loss) on termination of lease for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Termination of Lease 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-21 |
| 2022-12-31 | $149.00K 10-K · filed 2024-03-21 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |